“I am busy surviving” - Views about physical exercise in older adults scheduled for colorectal cancer surgery

ConclusionsTo engage frail older adults with CRC in preoperative exercise programs information on exercise should improve. Exercise programs should be easily accessible and take personal preferences, needs and abilities into account.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Four out of five metastatic colorectal cancers have already spread long before people are diagnosed, shows new study.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Conclusions: While case reports cannot be considered as proof of efficacy, these cases added to others of patients treated with the same method would suggest that this is a viable option for those patients whose disease cannot be treated successfully with other modalities. PMID: 31202206 [PubMed - in process]
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Tags: Altern Ther Health Med Source Type: research
ConclusionsCNS-RF is a relevant measure of prognosis in patients who have already achieved a period of remission. Providing an updated estimation of prognosis in the years following diagnosis may improve the survivors’ quality of life and access to credit or insurance.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Volume 47, Issue 1, December 2019, Page 2500-2506 .
Source: Artificial Cells, Blood Substitutes, and Biotechnology - Category: Biotechnology Authors: Source Type: research
Immunotherapy using chimeric antigen receptor (CAR)-engineered lymphocytes has shown impressive results in leukemia. However, for solid tumors such as colorectal cancer (CRC), new preclinical models are needed that allow to test CAR-mediated cytotoxicity in a tissue-like environment. Here, we developed a platform to study CAR cell cytotoxicity against 3-dimensional (3D) patient-derived colon organoids. Luciferase-based measurement served as a quantitative read-out for target cell viability. Additionally, we set up a confocal live imaging protocol to monitor effector cell recruitment and cytolytic activity at a single organ...
Source: EMBO Journal - Category: Molecular Biology Authors: Tags: Cancer, Immunology, Methods & Resources Source Type: research
Sir — We thank Laverty et al. for their correspondence and congratulations in response to our work.1 Please accept our apologies for the discrepancy in polyp categorisation. The revised polyp data in line with National Bowel Cancer Screening programme, the European Society of Gastrointestinal and Abd ominal Radiology (ESGAR) consensus guidelines2 and other published studies is as follows3,4: the total polyp detection rate was 13.5% (241 polyps) in 170 patients; 153 (63.5%) polyps were ≥10 mm in size compared to 88 (36.5%) measuring between 6–9 mm.
Source: Clinical Radiology - Category: Radiology Authors: Tags: Correspondence Source Type: research
ConclusionResults suggest reconsidering TAS-102 in patients with ECOG>  0, something that should be investigated in prospective randomized clinical trials.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewAdjuvant therapy for 6  months is the standard of care for stage III colon cancer. The use of oxaliplatin-based therapy over fluoropyrimidine alone increases toxicity, including dose-dependent peripheral neuropathy. Evaluation of a shorter duration of adjuvant therapy was therefore warranted, aiming to reduce toxicity wh ile maintaining clinical efficacy.Recent FindingsThe International Duration Evaluation of Adjuvant chemotherapy (IDEA) collaboration was a pivotal prospective pooled analysis of 6 randomized phase III trials across 12 countries. IDEA evaluated the non-inferiority of 3 versus 6...
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research
AbstractPurpose of ReviewColorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages of the disease. Treatment options are dependent on the stage of the disease, patients ’ performance status, and the specific molecular makeup of the tumor. Adding an anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) to conventional chemotherapy in molecularly selected patients (i.e., RAS wild-type) leads to a survival advantage. We aim to review the latest e vidence on the influence of primary tumor location (PTL) on treatment response to chemotherapy combined ...
Source: Current Colorectal Cancer Reports - Category: Cancer & Oncology Source Type: research
ConclusionRegorafenib-associated AEs are more common at an initiating dose of 160  mg. Considering that the efficacy depends on the dosage, 120 mg might be a better choice for mCRC and GIST patients; further studies are needed to validate the results of our analysis. Further prompt identification and management of AEs are required to help the patients continue with drug therapy .
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Geriatrics | Health Management | Netherlands Health | Sports Medicine | Study